Long Term Safety Study of Plecanatide
NCT02706483 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2272
Last updated 2020-08-18
Summary
Multi-center, open-label, long-term safety study
Conditions
- Irritable Bowel Syndrome
Interventions
- DRUG
-
Plecanatide
Sponsors & Collaborators
-
Bausch Health Americas, Inc.
lead INDUSTRY
Principal Investigators
-
Angela Bulawski · Bausch Health
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-01-31
- Primary Completion
- 2017-05-31
- Completion
- 2017-06-30
Countries
- United States
Study Locations
More Related Trials
-
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT00460811 ·Status: COMPLETED ·Phase: PHASE2
-
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
NCT00813098 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT03573908 ·Status: COMPLETED ·Phase: PHASE3
-
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
NCT00724126 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
NCT00730171 ·Status: COMPLETED ·Phase: PHASE3
-
Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
NCT03471728 ·Status: COMPLETED
-
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
NCT02559817 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
NCT01340053 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT00938717 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
NCT01923428 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
NCT00945334 ·Status: COMPLETED ·Phase: NA
-
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT02837783 ·Status: TERMINATED ·Phase: PHASE4
-
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
NCT00731679 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
NCT05905926 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients
NCT02078323 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
NCT01714843 ·Status: COMPLETED ·Phase: PHASE2
-
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
NCT04043455 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluate the Safety of Linaclotide in IBS-C Patients in China
NCT04462900 ·Status: COMPLETED
-
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
NCT02727751 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
NCT00948818 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
NCT01553591 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS)
NCT01542268 ·Status: UNKNOWN ·Phase: PHASE4
-
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
NCT02621892 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c
NCT00215566 ·Status: COMPLETED ·Phase: PHASE2
-
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
NCT02686138 ·Status: COMPLETED ·Phase: PHASE3